Announcement of the resolution of the third session of the 10th board of directors
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2018-004
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届3次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2018年4月9日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2018年4月20日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决方式召开。
(四)本次董事会会议应出席的董事9人,实际出席会议的董事9人,会议有效表决票数9票。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2017年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2017年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2017年度利润分配预案
经天健会计师事务所(特殊普通合伙)审计,2017年度公司合并报表归属于母公司股东的净利润为348,494,304.06元;母公司会计报表净利润194,066,681.11元。按母公司的本期净利润194,066,681.11元为基数,提取10%法定公积金19,406,668.11 元,加年初未分配利润570,339,566.43元,减去2016年度现金分红86,020,957.00元,本年度可供分配利润为658,978,622.43元。
公司2017年度拟进行现金分配,以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8 元(含税)。
2017年度不进行公积金转增股本。
董事会说明:
(1)现金分红政策执行情况
《公司章程》规定:公司最近三年以现金方式累计分配的利润不少于最近三年实现的年均可分配利润的百分之三十。
从2011年以来,公司连续进行了现金分红,已累计实施现金分红38881.47万元,最近三年现金分红情况如下(2017年度暂按上述预案计算,单位:万元):
|
分红年度 |
现金分红数额 |
当年合并归母公司净利润 |
现金分红占当年合并归母公司净利润比例 |
|
2015年 |
6193.51 |
20089.94 |
30.83% |
|
2016年 |
8602.10 |
28522.95 |
30.16% |
|
2017年 |
3440.84 |
34849.43 |
9.87% |
|
|
最近三年以现金方式累计分配 |
最近三年实现的年均可分配利润 |
最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例 |
|
|
18236.44 |
27820.77 |
65.55% |
公司最近三年以现金方式累计分配的利润占最近三年实现的年均可分配利润的比例为65.55%,符合公司《公司章程》规定的现金分红政策。
(2)公司的发展情况
目前,公司正处于发展的关键阶段,2018年公司将加快推进上海北卡项目,其子公司安徽新北卡化学有限公司需进行技术改造,建设“年产350吨医药中间体及900吨农药原药项目”;尖峰药业“DPT”项目进入一期临床试验,尖峰药业及其子公司浙江尔婴(原金得尔)、尖峰亦恩将进一步加大产品研发和引进力度;2018年度公司还将继续投入并完成尖峰国贸“新建仓库(电商物流园)项目”;上述业务的开展需要较大的资金支持。
(3)考虑到2018年公司在技改、新产品开发等方面的投入较大,为了保持公司的稳健经营,支持公司的长远发展,兼顾股东的短期和长期利益,董事会通过了上述2017年度利润分配预案。
(4)公司将召开2017年度业绩及现金分红说明会,就公司2017年度业绩及现金分红事项与投资者进行沟通和交流,及时答复投资者关心的问题。
(5)公司在召开股东大会审议上述2017年度利润分配预案时,将为投资者提供网络投票便利条件,同时按照参与表决的A股股东的持股比例分段披露表决结果。
独立董事意见:
(1)同意公司以2017年末股本344,083,828股为基数,每10股派发现金红利1.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为34,408,382.8元(含税),2017年度不进行公积金转增股本。
(2)该利润分配预案是根据公司2017年度实际经营成果及财务状况,结合公司未来业务发展的实际需要而制定。留存未分配利润主要用于满足公司公司发展的资金需求,有利于公司的持续健康发展,不存在损害股东特别是中小股东权益的情况。我们认为其符合《公司章程》对于利润分配的相关规定,符合公司的实际经营状况。
(3)公司董事会审议通过了上述利润分配预案。我们认为本次会议的召集、召开及审议表决程序符合相关法律、法规及《公司章程》的规定,合法有效;并同意将该预案提交公司2017年年度股东大会审议。
表决结果:同意9票、反对0票、弃权0票。
该预案将提交股东大会审议。
4、通过了聘请公司2018年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所(特殊普通合伙)为公司2018年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
5、通过了2017年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。2017年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
6、通过了关于对控股子公司提供担保的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
本议案需提交股东大会审议。
详见《对控股子公司提供担保的公告》(临2018-008)。
7、关于授权董事长利用自有资金进行委托理财的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权董事长利用自有资金进行委托理财的公告》(临2018-007)。
8、关于子公司日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘回避了该议案的表决。
详见《关于子公司日常关联交易公告》(临2018-006)。
9、通过了关于召开2017年度股东大会的议案
经审议与表决,董事会通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于召开2017年度股东大会的通知》(临2018-010)。
10、通过了2017年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
11、通过了关于新北卡化学技术改造项目的议案
董事会审议并通过了该议案。同意子公司安徽新北卡化学有限公司投资16274.25万元,其中:固定资产投资为13274.25万元,流动资金3000万元。建设“年产350吨医药中间体及900吨农药原药项目”。
表决结果:同意9票、反对0票、弃权0票。
12、通过了2017年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,2017年度可提取中长期激励基金为13836266.94元。
表决结果:同意9票、反对0票、弃权0票。
13、通过了董事会审计委员会2017年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
14、通过了独立董事2017年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
15、通过了2017年度董事会工作报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的独立意见:
公司独立董事对上述4、6、7、8、12五项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、上网公告附件
公司第十届独立董事对上述相关事项的独立董事意见。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一八年四月二十四日
More information
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-22
Peak International Trade was rated as "excellent delivery warehouse" by the big business"
On April 12, the 2019 Dalian Commodity Exchange Industrial Products Delivery Work Summary Meeting was held in Dalian. Jianfeng International Trading Company was rated as "2018 (Industrial Products) Excellent Delivery Warehouse" and Ruan Weihang, an employee of the International Trading Company, was rated as "2018 (Industrial Products) Excellent Futures Specialist in Designated Delivery Warehouse". The delivery link is the bridge link between the futures and cash markets, an important area of risk prevention and control in the futures market, and a strong guarantee for the smooth operation and function of the market. Since obtaining the qualification of PVC delivery warehouse in 2009, the chemical warehousing and logistics business of international trading company has developed steadily. In terms of management, the international trading company strictly follows the various systems of the Dalian Commodity Exchange to implement warehouse-in and warehouse-in management. The management level has been improved year by year. Broken packages have been handled on the spot, and the loss of goods has been greatly reduced. The management goal of daily clearing has been achieved, and standardized operations have been achieved; in terms of business marketing, the futures business has driven the gradual development and growth of the spot business, futures varieties have developed from a single PVC variety to four varieties of PVC, PP, PE and plywood. The business volume has increased year by year and has exceeded 500000 tons. The operation volume can exceed 2500 tons/day; In terms of customer service, from zero experience in futures business to now, customer reputation has increased year by year, and customer complaints have gradually decreased. The annual excellent delivery warehouse of the judges is the full affirmation of Dalian Commodity Exchange on the functions of international trading companies, market satisfaction, futures management level and standardization of warehouse daily management. Lou Chunming, general manager of the international trading company, said that the international trading company will implement
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-30
Peak Cement Won the Bid for National Key Project Daye Peak Becomes Huang-Huang Railway Supplier
On March 19, Daye Jianfeng Cement Company officially received a notice from China Railway Construction Material Collection Center that the company was shortlisted for the new Huang (Mei) Huang (Zhou) railway project in the Hubei section of the Shanghai-Chengdu high-speed railway along the Yangtze River in the second place, and obtained the right to supply the 6th package of cement. This is the first stick undertaken by Daye Jianfeng in 2019, and it is also the second time to enter the high-speed rail project after the Wu (Han) Jiu (Jiang) high-speed rail. The Huanghuang high-speed railway is a component of the "eight vertical and eight horizontal" high-speed railway network in the "National Medium and Long-term Railway Network Plan". It is a component of the Wuhan-Hangzhou and Beijing-Hong Kong-Kowloon high-speed railway network. It has a total length of 125 kilometers and a design speed of 350 kilometers per hour. It will start construction at the end of 2018. It will be opened to traffic in 2021. In addition to the characteristics of large demand for high-speed railway and highway projects, the project time span is long and the product quality requirements are high, especially the high-speed railway project has extremely strict requirements on the alkali content of cement. After participating in the bidding, Yuan Xianming, executive deputy general manager of Daye Peak, organized production, quality control, procurement and other relevant departments for many times to carry out tests on the production of low-alkali cement and adjust the proportion of raw materials. The quality control department also sent samples to the provincial professional inspection department for comparative inspection to ensure product stability. The marketing department carefully checked the details of the tender, strictly checked and repeatedly deduced the bid price. Finally, with the full cooperation of all departments, the successful bidding was passed, finalist Huang-Huang high-speed rail project. It is understood that as the country continues to increase investment in infrastructure transportation construction, daye peak adjusted its work direction at the end of 2018, requiring marketing work in 2019 to focus on key projects.
2020
07-31
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-22
Daye Peak Opens "Standard Year"
After the 2019 overhaul ended in early March, Daye Jianfeng Cement Company immediately launched the "Standard Year" activity to carry out standardized rectification in view of a series of defects and problems in the daily management process. The goal of the "Standard Year" activity is to target specific issues that affect employees' work efficiency and safe and environmentally friendly production. Through the formulation of institutionalized work standards, further standardize employees' various operations, improve operational efficiency, and improve grassroots management execution, so as to achieve The purpose of improving the company's image, reducing costs, improving efficiency, and increasing benefits. In order to ensure the smooth progress of the activities, daye peak has set up a promotion team headed by general manager Zhang fengliang to be responsible for the overall promotion of the "standard year" activities, mainly including revising the activity plan, summarizing the standardized implementation standards of various departments, implementing the plan, supervising the implementation progress, evaluating the implementation effect, collecting suggestions and opinions in the implementation process, etc. Based on the foundation, aiming at the details and solving problems is a major feature of Daye peak's "standard year" activity. For example, the "Flange Sealing Operation Standard", which is currently being tried out, not only puts forward standardization requirements for such a "trivial matter" in equipment management as flange sealing, but also attaches "model" photos to make it clear to mechanics What should be done and what should be done. However, this "small standard" aims at three problems: leakage at the production site, extensive mechanic work and waste of materials. Once it becomes the behavior habit of employees, the hygiene and cost control at the production site are bound to be improved. It is understood that Daye peak "standard year" activities plan to continue for three years to promote, activities
2020
07-31